This effect may be attributed to the potential reprogramming of prostatic stem and progenitor cells as a result of early estrogen exposure, leading to changes in their proliferation status . Neonatal exposure to high levels of estrogen may permanently alter prostate development and differentiation . This enzyme has been found to be expressed in Leydig cells, germ cells, and epididymal sperm . During fetal development, INSL3 expression starts after gonadal sex determination and acts by binding to the RelaXin-like Family Peptide receptor 2 (RXFP2), which is expressed by gubernacular ligament mesenchymal cells that connect the testis to the inguinal wall . This reduction in AMH is linked to the maturation of Sertoli cells and inversely correlates with circulating androgen levels . As puberty progresses, Sertoli cells transition from a proliferative, immature state to a mature, quiescent one, leading to a marked decrease in AMH levels .
This decrease may be attributed to the inhibitory effects of high levels of placental estrogen on HPG axis activity at the end of pregnancy . GnRH expression begins in the first trimester, while levels of LH and FSH can be detected in the fetal serum and pituitary gland, starting at approximately 12 weeks of gestation in the second trimester (Figure 4). The HPG axis is the center of human reproduction, and its activation depends on the secretion of GnRH by the hypothalamus follows a pulsatile pattern.
DHT binds to the same receptors as testosterone. LH and FSH are known as gonadotropins. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript. This work was supported by a "Departments of Excellence Programme" grant from the Italian Ministry for Education, University and Research to the Department of Biomedical, Metabolic and Neural Sciences (University of Modena and Reggio Emilia). Significant steps forward in the elucidation of gonadotropin signaling and regulation have been made in recent years.
Informed consent from patients were not needed as the study included a retrospective review of the medical records involving minimal risk to the patients. Testosterone levels were assessed by standard second or third generation laboratory assays including chemiluminescent immunoassay and liquid chromatography tandem mass spectrometry. Patients were divided into 2 groups based on the treatment they received for induction of puberty (hCG or testosterone). This study included pre-pubertal males with HH, referred to the Pediatric Endocrinology Clinic at Texas Children’s Hospital between 2012 and 2018. Several guidelines recommend different gonadotropin regimens10-12 for pubertal induction. Gonadotropin therapy represents an alternative to androgen therapy for stimulation of pubertal changes in HH males. Congenital HH is more common in males, with an estimated prevalence of about 1 to 10 in 100,000 live births.
The events of these cycles and the hormone actions during them are summarized in Figure 2. In addition, estrogens and progesterone are released from the developing follicles. At the onset of puberty, the hypothalamus causes the release of FSH and LH into the male system for the first time. This causes the release of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary into the blood. You need GnRH to make follicle-stimulating hormone and luteinizing hormone. In children, too much GnRH can bring on early puberty, while too little hormone can delay puberty.